Capstone Investment Advisors
ACAD icon

Capstone Investment Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Capstone Investment Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$506K Buy
+22,735
New +$543K ﹤0.01% 1131
2024
Q2 		– Sell
-11,403
Closed -$211K – 2037
2024
Q1 		$211K Buy
+11,403
New +$283K ﹤0.01% 1998

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Capstone Investment Advisors's ACAD Position: Q1 2026 in Review

Capstone Investment Advisors opened a new position in Acadia Pharmaceuticals (ACAD) in Q1 2026: 22,735 shares worth $506K. The stake represents ﹤0.01% of the portfolio and ranks #1131 among its holdings. This is a return to the name: Capstone Investment Advisors previously reported a position in ACAD as recently as Q1 2024.

Capstone Investment Advisors first reported a position in ACAD in Q1 2024 and has held it in 2 quarters since. 340 funds tracked by Wall St. Rank hold ACAD as of Q1 2026.

  • Capstone Investment Advisors held 22,735 shares of Acadia Pharmaceuticals worth $506K as of Q1 2026.
  • Acadia Pharmaceuticals was a new Capstone Investment Advisors position in Q1 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q1 2026, its #1131 holding.
  • Capstone Investment Advisors first reported a position in Acadia Pharmaceuticals in Q1 2024 and has held it in 2 quarters since.
  • 340 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2026.

Based on Capstone Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.